BETA
LAX.SH
BETA DRUGS LIMITED·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
1,971
+18.39%O:1664.7
H:1997.6
L:1616
C:1971
52W Range
990.12807.9
+99%/-30%
Market Cap
₹2,192.00 Cr
Traded: ₹106.60 Cr (4.86%) 0.0x
Free Float: ₹381.41 Cr (27.95% of FF traded)
Volume · 60D trend
5.67 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
1W:+0% 1M:-5% 3M:-14% 6M:+1% 12M:+47%
RS Score
SEEM
NOUS
BNF
SMA Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
P/E40.8
P/B5.0
P/S4.9
EV/EBIT22.4
Business Strength
ROE25.8%
ROCE27.3%
OPM19.7%
NPM10.7%
Growth (3Y CAGR)
EPS-2.6%
Sales+19.0%
Profit+11.0%
3Y Return+30.0%
Balance Sheet
Debt/Equity0.1
Debt48.7 Cr
Pledge0.0%
CWIP/Fixed Asset4.1%
Cash Position
CFO/NP90.2%
FCF-16.2 Cr
FCF 3Y Avg2.4 Cr
Cash/MCap7.0%
Others
Div Yield0.0%
Div Payout0.0%
Cash Conv. Cycle100 days
Tradeable Free Float17.4%
NOUS
BNF
MCap₹2,192.00 Cr2.2K Cr
Vol5.67 L
RVol
Del%
TVal106.6 Cr
RS
SEEM
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Current
₹ 5.11 Cr
1.34% FF
60d high
₹ 9.60 Cr
60d low
₹ 3.70 Cr
60d mean
₹ 5.60 Cr
vs mean
▼ 8.78%
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +27.0% | +19.0% | -- | +15.0% | Decelerating |
| ROE | -- | +25.0% | +23.0% | -- | -- | Decelerating |
| Return | -- | +33.0% | +30.0% | +3.0% | -- | Decelerating |
| Profit | -- | +29.0% | +11.0% | -- | +15.0% | Stable |
Quarterly Results
Sep 2024
Rev
▲180 Cr
+28% YoY+17% QoQ
OPM22.0%
NPM13.3%
PAT
--▲24 Cr
EPS
+23% YoY▲24.2
Mar 2024
Rev
▲154 Cr
+34% YoY+9% QoQ
OPM18.0%
NPM11.0%
PAT
--▼17 Cr
EPS
+11% YoY▼16.4
Sep 2023
Rev
▲141 Cr
+26% YoY+23% QoQ
OPM23.0%
NPM14.2%
PAT
--▲20 Cr
EPS
+26% YoY▲19.7
Mar 2023
Rev
▲115 Cr
+20% YoY+3% QoQ
OPM23.0%
NPM13.0%
PAT
--▼15 Cr
EPS
+14% YoY▼14.7
Sep 2022
Rev
▲112 Cr
+27% YoY+17% QoQ
OPM24.0%
NPM14.3%
PAT
--▲16 Cr
EPS
+35% YoY▲15.7
Mar 2022
Rev
▲96 Cr
+48% YoY+9% QoQ
OPM24.0%
NPM13.5%
PAT
--▲13 Cr
EPS
+100% YoY▲12.9
Sep 2021
Rev
▲88 Cr
+73% YoY+35% QoQ
OPM23.0%
NPM13.6%
PAT
--▲12 Cr
EPS
+127% YoY▲11.6
Mar 2021
Rev
▲65 Cr
+48% YoY+27% QoQ
OPM22.0%
NPM10.8%
PAT
--▲7 Cr
EPS
+52% YoY▲6.5
Sep 2020
Rev
▲51 Cr
+9% YoY+16% QoQ
OPM21.0%
NPM9.8%
PAT
--▲5 Cr
EPS
+1% YoY▲5.1
Mar 2020
Rev
▼44 Cr
---6% QoQ
OPM19.0%
NPM9.1%
PAT
--▼4 Cr
EPS
--▼4.3
Sep 2019
Rev
47 Cr
----
OPM20.0%
NPM10.6%
PAT
--5 Cr
EPS
--5.1
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Debt / Equity0.11
Interest Coverage13.9x
Promoter Pledge0.0%
Borrowings49 Cr
Efficiency
Receivable Days113 days
Inventory Days159 days
Payable Days172 days
Cash Conversion cycle100 days
Cash Position
Operating Cash Flow37 Cr
Investing Cash Flow-51 Cr
Financing Cash Flow-8 Cr
Free Cash Flow-16 Cr
Detailed Financials
Sep 2026PDF ↗ | Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024 | Mar 2024 | Sep 2023 | Mar 2023 | Sep 2022 | Mar 2022 | Sep 2021 | Mar 2021 | Sep 2020 | Mar 2020 | Sep 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 137 | 126 | 94 | 87 | 103 | 100 | 94 | 88 | 180 | 154 | 141 | 115 | 112 | 96 | 88 | 65 | 51 | 44 | 47 |
| Expenses | 107 | 98 | 76 | 70 | 82 | 81 | 76 | 70 | 141 | 127 | 108 | 88 | 86 | 73 | 68 | 51 | 41 | 36 | 37 |
| Operating Profit | 30 | 27 | 18 | 17 | 21 | 20 | 17 | 18 | 39 | 27 | 33 | 26 | 27 | 23 | 20 | 14 | 11 | 8 | 9 |
| Other Income | 2 | 2 | 3 | 2 | 3 | 3 | 2 | -1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2 | 3 | 4 | 4 | 4 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 3 | 6 | 4 | 5 | 6 | 5 | 4 | 3 | 4 | 3 | 2 | 2 |
| Profit Before Tax | 26 | 22 | 12 | 10 | 16 | 16 | 12 | 12 | 33 | 22 | 27 | 20 | 21 | 18 | 16 | 9 | 7 | 5 | 7 |
| Tax % | 25.0% | 25.0% | 24.0% | 19.0% | 26.0% | 25.0% | 26.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 27.0% | 28.0% | 30.0% | 21.0% | 14.0% | 27.0% |
| Net Profit | 19 | 16 | 9 | 9 | 12 | 12 | 9 | 9 | 24 | 17 | 20 | 15 | 16 | 13 | 12 | 7 | 5 | 4 | 5 |
| Exceptional Items | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -2 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 16.7 | 14.3 | 8.9 | 8.4 | 12.1 | 11.6 | 8.9 | 8.9 | 24.2 | 16.4 | 19.7 | 14.7 | 15.7 | 12.9 | 11.6 | 6.5 | 5.1 | 4.3 | 5.1 |
| Sales Growth (YoY) | 33.0% | 26.0% | 0.0% | -1.1% | -42.8% | -- | -39.0% | -- | 27.7% | 33.9% | 25.9% | 19.8% | 27.3% | 47.7% | 72.5% | 47.7% | 8.5% | -- | -- |
| Sales Growth (QoQ) | 8.7% | 34.0% | 8.1% | -15.5% | 3.0% | 6.4% | 6.8% | -51.1% | 16.9% | 9.2% | 22.6% | 2.7% | 16.7% | 9.1% | 35.4% | 27.4% | 15.9% | -6.4% | -- |
| OP Growth (YoY) | 42.9% | 35.0% | 5.9% | -5.6% | -46.2% | -- | -37.0% | -- | 18.2% | 3.8% | 22.2% | 13.0% | 35.0% | 64.3% | 81.8% | 75.0% | 22.2% | -- | -- |
| OP Growth (QoQ) | 11.1% | 50.0% | 5.9% | -19.0% | 5.0% | 17.6% | -5.6% | -53.8% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Profit Growth (YoY) | 52.0% | 35.0% | -15.0% | -20.0% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | 38.1% | 22.9% | -0.2% | -5.2% | -50.0% | -- | -45.4% | -- | 23.0% | 11.3% | 25.5% | 13.8% | 34.7% | 99.8% | 126.7% | 52.5% | 1.2% | -- | -- |
| EPS Growth (QoQ) | 17.4% | 59.6% | 6.3% | -30.6% | 4.5% | 29.5% | 1.0% | -63.4% | 47.6% | -16.6% | 33.5% | -6.0% | 21.0% | 11.3% | 79.5% | 26.3% | 20.7% | -16.2% | -- |
| OP Margin | 21.9% | 21.4% | 19.1% | 19.5% | 20.4% | 20.0% | 18.1% | 20.4% | 21.7% | 17.5% | 23.4% | 22.6% | 24.1% | 24.0% | 22.7% | 21.5% | 21.6% | 18.2% | 19.1% |
| Net Margin | 13.9% | 12.7% | 9.6% | 10.3% | 11.7% | 12.0% | 9.6% | 10.2% | 13.3% | 11.0% | 14.2% | 13.0% | 14.3% | 13.5% | 13.6% | 10.8% | 9.8% | 9.1% | 10.6% |
| Material Cost % | 44.1% | 43.4% | 38.4% | 41.3% | 47.7% | 49.6% | 46.9% | 47.9% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Employee Cost % | 14.9% | 16.3% | 19.9% | 19.3% | 15.9% | 16.0% | 16.2% | 15.8% | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/S | 4.94 | 4.52 | 5.97 | 3.09 | 1.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 40.80 | 36.97 | 58.06 | 29.75 | 12.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.00 | 7.56 | 9.22 | 6.44 | 4.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Annual Reports
9Credit Ratings
6Concalls
10Nov 2025
30 Nov 2025May 2025
31 May 2025Nov 2024
30 Nov 2024May 2024
31 May 2024Nov 2023
30 Nov 2023May 2023
31 May 2023Nov 2022
30 Nov 2022May 2022
31 May 2022Dec 2021
31 Dec 2021May 2021
31 May 2021